Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Where they overlap and where they don't Complementary Mechanism Targets Target Origin BPC-157 Gastric juice protein fragment (15 amino acids) TB-500 Thymosin Beta-4 fragment (LKKTETQ region) Target Primary action BPC-157 Local tissue repair signaling TB-500 Systemic cell migration and mobilization Target Angiogenesis BPC-157 VEGF upregulation, NO pathway TB-500 Endothelial migration, VEGF crosstalk Target Cell migration BPC-157 Indirect, via growth factors TB-500 Direct (G-actin sequestering) Target Best-evidence tissue BPC-157 Tendon, gut, gastric mucosa (preclinical) TB-500 Cardiac, corneal, skin (preclinical + early human T4) Target Reported in vivo half-life BPC-157 ~4 hours (animal estimates) TB-500 ~23 days (animal estimates) Half-life figures are pharmacokinetic estimates from animal studies
Spontaneous Erections (Men) MC4R activation in the hypothalamus triggers oxytocin release, which can produce erections 1-5 hours after injection
Further investigations using vascular endothelial cells suggested that BPC-157 might have increased mRNA and protein expressions of VEGFR2, but not VEGF-A
In laboratory studies, 5-Amino-1MQ has been evaluated for its interaction with nicotinamide N-methyltransferase (NNMT)-associated enzymatic pathways and downstream NAD+-related and methylation signaling under controlled experimental conditions
